Clinical Cancer Research Landon Prizes for Basic and Translational Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 3244-3249, June 1, 2007. doi: 10.1158/1078-0432.CCR-06-2616
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Christensen, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Christensen, I. J.

Imaging, Diagnosis, Prognosis

Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival

Julia S. Johansen1, Klaus Brasso2,5, Peter Iversen2, Børge Teisner6, Patrick Garnero7, Paul A. Price8 and Ib Jarle Christensen3,4

Authors' Affiliations: Departments of 1 Rheumatology, Herlev Hospital, 2 Urology and 3 Finsen Laboratory, Rigshospitalet, 4 Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, and 5 Research Centre for Prevention and Health, Copenhagen, Denmark, 6 Department of Immunology and Microbiology, University of Odense, Odense, Denmark, 7 Institut National de la Sante et de la Recherche Medicale Research Unit 664 and Molecular Markers, Synarc, Lyon, France; and 8 Department of Biology, University of California San Diego, La Jolla, California

Requests for reprints: Julia S. Johansen, Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Phone: 45-44884243; Fax: 45-44884214; E-mail: julia.johansen{at}post3.tele.dk.


   Abstract
Top
 Abstract
Patients and Methods
 Results
 Discussion
 References
 
Purpose: Elevated serum levels of biochemical markers of bone turnover and YKL-40 in patients with metastatic prostate cancer (PC) at the time of diagnosis are associated to poor prognosis. In this study, we evaluated the value of these biomarkers in monitoring the patients during hormonal treatment.

Experimental Design: Serum procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (BAP), CTX-I, and YKL-40 were determined by ELISA in a longitudinal study of 106 patients with metastatic PC during treatment with total androgen ablation or parenteral estrogen. Serum samples were collected with 3 months interval. Median observation time was 4.9 years (range, 3.6-6.2). A total of 78 patients died (64 within 7 months following the last blood sampling).

Results: After 6 months treatment, serum PINP, BAP, and YKL-40 decreased (P < 0.0001), but not serum CTX-I compared with baseline values. Univariate Cox analysis showed that serum PINP at 6 months [log transformed and treated as a continuous variable; hazard ratio (HR), 2.2; P < 0.0001], serum BAP (HR, 1.8; P < 0.0001), and serum CTX-I (HR, 2.4; P < 0.0001), but not serum YKL-40 (HR, 1.4; P = 0.16) were associated with survival. Multivariate Cox analysis including the biomarkers 6 months after the start of treatment showed that Soloway score (HR, 3.9; P = 0.013), WHO tumor grade (HR, 3.9; P = 0.004), and serum PINP (HR, 2.2; P < 0.0001) were independent prognostic variables of survival. Scoring the biomarkers during treatment as time-dependent covariates in univariate Cox regression analysis showed that increases in serum PINP (HR, 2.0; P < 0.0001), BAP (HR, 2.1; P < 0.0001), and YKL-40 (HR, 2.1; P < 0.0001) were predictors of early death.

Conclusions: Serial monitoring of serum PINP, BAP, CTX-I, and YKL-40 in metastatic PC patients during hormonal treatment provided information of prognosis.

Prostate cancer (PC), the most frequent cancer in males, is responsible for ~27,350 deaths in the United States in 2006 (1). The optimal management of patients with metastatic PC is still a question open for debate (2). The ongoing discussions reflect the fact that once patients have developed metastatic disease and the PC has become hormone refractory, the prognosis is poor (3). Bone is the most common site of PC spread and accounts for up to 80% of all PC metastases, and 85% to 100% of those who die from PC have bone metastases (3). The high frequency and poor prognosis of patients with metastatic PC emphasize the need for good biomarkers of treatment response, disease progression, and short survival to optimize treatment of PC patients.

Several biomarkers (defined as physical signs or laboratory measurements that occur in association with a pathologic process or that have putative and/or prognostic utility; ref. 4) of bone resorption [e.g., urine N-telopeptide of type I collagen (NTX-I), serum or urine C-telopeptide of type I collagen (CTX-I)] and bone formation [e.g., serum bone-specific alkaline phosphatase (BAP), osteocalcin, the amino (NH2)- and carboxy (COOH)-terminal extension propeptides of type I procollagen (PINP and PICP)] are increased in PC patients with bone metastasis (5–12). Recently, three large studies of PC patients with bone metastases showed that high serum CTX-I and NTX-I (8), urine NTX-I (9, 10, 12), serum BAP (8–10, 12), and PINP (8) were predictors of short survival. In PC patients with bone metastases treated with the bisphosphonate zoledronic acid, high urine NTX-I and serum BAP in the most recent sample before an event were associated with a risk of skeletal morbidity, bone lesion progression, and death (10).

We have recently reported elevated serum PINP in most patients with PC and bone metastasis and elevated serum BAP, CTX-I, and YKL-40 in approximately half of the patients compared with healthy subjects (11). The three biomarkers of bone remodeling were related to the burden of PC in the skeleton determined by the Soloway score (11). All four biomarkers at the time of diagnosis and before endocrine therapy were prognostic predictors of survival. Serum PINP in combination with serum YKL-40, performance status, WHO grade, and Soloway score were independent prognostic parameters of poor prognosis (11).

Serum YKL-40 is a new biomarker with a prognostic value of survival in patients with other solid tumors and hematological malignancies (13). YKL-40 may play a role in proliferation and differentiation of cancer cells and protect them from apoptosis, although in vivo proof is yet to be obtained. YKL-40 is a growth factor for fibroblasts and chondrocytes (14, 15), acts synergistically with insulin-like growth factor-I (15), is regulated by tumor necrosis factor-{alpha} (16, 17), requires sustained activation of NF-{kappa}B (17), binds to collagen types I, II, and III, and modulates the rate of type I collagen fibril formation (18).

In the present retrospective, longitudinal study of PC patients with bone metastases, we have evaluated if serial measurement of serum PINP, BAP, CTX-I, and YKL-40 may provide an early assessment of response to endocrine therapy and if these biomarkers can be used to predict death during follow-up.


   Patients and Methods
Top
 Abstract
 Patients and Methods
Results
 Discussion
 References
 
Patients and treatments. Retrospective, longitudinal study included 106 men (median age, 72; range, 54-89 years) with metastatic PC (stage T1-4, Nx, M+, Soloway score 1-3) and a WHO performance status of 0 to 2. The patients were enrolled from five Danish hospitals and included in the Scandinavian Prostate Cancer Group-5 study of patients with metastatic PC (19). The patients were included between November 1993 and June 1996 and randomized to treatment with either total androgen ablation (either bilateral orchiectomy or triptorelin 3.75 mg/mo combined with the antiandrogen flutamide 250 mg thrice daily) or parenteral estrogen [i.m. injections of 240 mg polyestradiol phosphate every second week for the first 8 weeks (5 doses), followed by a maintenance dose of 240 mg/mo]. The choice between orchiectomy and triptorelin was at the discretion of the clinician and patient. Staging was based on histologic and/or cytologic findings and digital rectal examination, and assessment of bone metastases at diagnosis was based on plain X-ray skeletal surveys and radioisotopic bone imaging. The extent of osseous dissemination was graded according to Soloway et al. (20). Patients previously given systemic treatment for PC, previously diagnosed with another malignant disease, myocardial or cerebral infarction within the past month, with previous or present liver disease, or not believed capable of following the study rules were excluded.

The patients were followed in the outpatient clinic every 3 months until death or January 31, 2000. The median follow-up time was 4.9 years (range, 3.6-6.2 years). Time to death was measured from the date of starting treatment. A total of 78 (74%) patients died in the follow-up period, and 64 within 7 months following the last blood sampling. The study was done in accordance with the Helsinki II declaration. The patients were informed about the possibility of withdrawing from the study at any time. The Central Ethics Committee and The Danish Board of Health approved the study.

Healthy controls. The reference range of serum BAP in 126 healthy men >25 years was provided by Quidel. The reference range of serum CTX-I in 115 healthy men aged 41 to 80 years was provided by Synarc Laboratory. The reference range of serum PINP and YKL-40 was determined in 93 healthy men >25 years (median age, 51; range, 26-73). They were all healthy, were not taking any medicine, and had no signs or symptoms of cancer, joint, liver, metabolic, or hormonal disease.

Biomarkers. Nonfasting blood samples were collected at the time of inclusion, after 4 weeks of treatment, and then every 3 months until death or January 31, 2000. Serum was only available for measurement of CTX-I from 73 patients at 6 months. Urine was not collected. Serum was collected between 8:00 a.m. and 1:00 p.m. and separated from blood cells within 3 h after venipuncture by centrifugation at 3,000 rpm for 10 min. Serum was stored in aliquots at –80°C until analysis. Serum PINP was determined by an in-house ELISA, which measures both molecular forms of PINP (21). The detection threshold is 0.5 µg/L, intra- and interassay variations are <5.3%. The median serum PINP in controls is 49 µg/L [range, 24-143 µg/L; cut-point, 66 µg/L (95th percentile)]. Serum BAP was determined by ELISA (Quidel; ref. 22). The sensitivity is 0.7 units/L, intra- and interassay variations are <5.8% and 7.6%. The median serum BAP in controls is 23 units/L (range, 15-41 units/L; cut-point, 41 units/L). Serum CTX-I was determined by a two-site immunoassay (Roche Diagnostic; ref. 23). The sensitivity is 0.01 µg/L, and intra- and interassay variations are <4% and 6%. The median serum CTX-I in controls is 0.300 µg/L [range, 0.07-0.72 µg/L; cut-point, 0.638 µg/L (95th percentile)]. Serum YKL-40 was determined by ELISA (Quidel; ref. 24). The sensitivity is 20 µg/L, and intra- and interassay variations are <3.6% and 5.3%. The median serum YKL-40 in controls is 47 µg/L (range, 20-184 µg/L; 95th percentile is 104 µg/L). Serum YKL-40 increases with age in controls, and the age-adjusted 95th percentile is set as cut-point.

Statistical analyses. The SAS software package (version 9.1; SAS Institute) was used. Rank statistics were used for estimation of correlation coefficients and paired tests. The end point for survival analysis was death of all causes. Serum PINP, BAP, CTX-I, and YKL-40 at 6 months were analyzed using the landmark method, i.e., from time of 6 months sample to death. The Kaplan-Meier method was used to estimate survival probabilities. The log-rank test was used to test for equality of strata. The Cox proportional hazards model was applied for multivariate analysis. The assumption of proportional hazards was verified graphically. Serum PINP, BAP, CTX-I, and YKL-40 were loge transformed and treated as continuous variables for the uni- and multivariate Cox analyses of survival.

Analysis of repeated measurements was done using time-dependent covariates in the Cox proportional hazards model. Samples taken at ~3-month intervals were available and entered into the Cox regression model with updated values scored by the log of the actual level. Only the updated covariates were used in this analysis that is the biomarker levels. Patients without an updated measurement within 7 months after the latest update were removed from the risk set and only reentered if a measurement subsequently was available. P values <5% were considered significant.


   Results
Top
 Abstract
 Patients and Methods
 Results
Discussion
 References
 
Early changes in the biomarkers. At baseline, all four biomarkers were elevated (P < 0.001) in the patients with metastatic PC compared with healthy men (Table 1 ). After 6 months of treatment with either total androgen ablation or parenteral estrogen serum PINP, BAP, and YKL-40 decreased significantly, but not serum CTX-I (Table 1). Serum PINP and BAP at baseline and after 6 months of treatment were correlated (RT0 = 0.85; RT6 = 0.85; P < 0.0001). Serum CTX-I correlated with PINP at baseline and 6 months (RT0 = 0.84; RT6 = 0.73; P < 0.0001) and with BAP (RT0 = 0.67; RT6 = 0.63; P < 0.0001). Neither serum PINP, BAP, nor CTX-I correlated with YKL-40 at baseline and after 6 months. Significant correlations were found between the baseline and 6 months value for all biomarkers (PINP: R = 0.78; BAP: R = 0.72; CTX-I: R = 0.68; and YKL-40: R = 0.67; P < 0.0001).


View this table:
[in this window]
[in a new window]

  		Table 1. Changes in serum PINP, BAP, CTX-I, and YKL-40 levels in patients with metastatic prostate carcinoma after 6 mo of treatment with total androgen ablation or parenteral estrogen

 
The differences between the baseline level and the level after 6 months of treatment were not different between the three treatment groups for serum PINP (P = 0.24), BAP (P = 0.63), and YKL-40 (P = 0.20). The median difference between the baseline and 6 months concentration for serum CTX-I was –0.12 (range, –2.26 to 0.41) for the group treated with parenteral estrogen and significantly different (P = 0.01) from the differences in serum CTX in the group treated with bilateral orchiectomy and antiandrogen flutamide (median difference, 0.12; range, –0.59 to 0.64) and the group treated with triptorelin and the antiandrogen flutamide (median difference, 0.10; range, –2.78 to 0.61).

Biomarkers after 6 months of treatment and survival. In the original paper, no difference was found in overall survival in the two treatment groups (19). In the present study of 106 patients, their survival was independent of treatment; thus, all patients were evaluated together for survival analysis. No interaction between treatment, the biomarkers, and survival could be shown. The serum concentrations of the biomarkers after 6 months of treatment were log transformed and treated as continuous variables in uni- and multivariate analysis.

Serum samples were available at 6 months from 102 patients for PINP, BAP, and YKL-40 determination and from 73 patients for CTX-I determination. In the set with complete data including serum CTX-I (N = 73), the analysis of survival for baseline and 6 months levels showed that the 6-month levels were the best predictors of overall survival, and that the change from baseline level was not significant. The results from the 73 patients are shown in Table 2 (left and middle) and from the 102 patients in Table 2 (right). Serum PINP, BAP, and CTX-I were significant in the univariate setting, but only serum PINP was significant in the multivariate model. Serum BAP is closely associated to PINP and, therefore, not included in the multivariate analysis. The ratio of the 6-month level to baseline level was not significant for any of the biomarkers (PINP: P = 0.78; BAP: P = 0.30; CTX-I: P = 0.47; YKL-40: P = 0.77).


View this table:
[in this window]
[in a new window]

  		Table 2. Univariate and multivariate Cox regression analyses of the four biomarkers at 6 mo after treatment start and the clinical parameters at start of treatment in patients with metastatic prostate carcinoma

 
Figure 1 illustrates the survival plots when the patients were grouped by tertiles according to serum PINP, BAP, and YKL-40 (n = 102) and serum CTX-I (n = 73) at 6 months of treatment. Significantly shorter survival was found between the three groups of patients according to increasing level for serum PINP. Patients with normal or a small increase in serum BAP and CTX-I had similar survival, whereas patients with serum BAP and CTX-I in the highest tertile had shorter survival compared with the other groups. There was no difference in survival stratifying serum YKL-40 by tertiles.


Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 1. The impact of serum PINP (A), BAP (B), CTX-I (C), and YKL-40 (D) level at 6 mo after start of treatment with total androgen ablation or parenteral estrogen on overall survival of patients with metastatic prostate carcinoma. Patients were divided into three groups according to serum PINP, BAP, CTX-I, and YKL-40 obtained at 6 mo after treatment start. Left, numbers of events for each group; and the numbers of patients at risk are shown for 0, 24, and 48 mo. Serum samples were available at 6 mo from 102 patients for PINP, BAP, and YKL-40 determination and from 73 patients for CTX-I determination. A, group 1: serum PINP <78 µg/L; group 2: serum PINP ≥78 and ≤169 µg/L; and group 3: serum PINP >169 µg/L. B, group 1: serum BAP <24 units/L; group 2: serum BAP ≥24 and ≤59 units/L; and group 3: serum BAP >59 units/L. C, group 1: serum CTX-I <0.32 µg/L; group 2: serum CTX-I ≥0.32 and ≤0.72 µg/L; and group 3: serum CTX-I >0.72 µg/L. D, group 1: serum YKL-40 <72 µg/L; group 2: serum YKL-40 ≥72 and ≤133 µg/L; and group 3: serum YKL-40 >133 µg/L.

 
Changes in the biomarkers during follow-up and prediction of early death. Serum PINP, BAP, and YKL-40 were measured in 106 patients during follow-up with time intervals of ~3 months. Seventy-eight (74%) died in this period. A total of 784 serum samples were collected during follow-up. The median number of samples collected from each patient was 6 (range, 1-24 samples; 2-4 samples, 38%; 5-8 samples, 30%; 9-12 samples, 13%; ≥13 samples, 20%). Serum CTX-I was only measured at baseline and 6 months in 73 patients.

The changes in serum PINP and BAP were closely associated with a rank correlation of 0.80. The changes in serum YKL-40 were not as closely related to the markers of bone formation with rank correlation of 0.18 and 0.11, respectively. In patients with blood samples collected a few months before death, increases in all biomarkers were often observed.

Serum PINP, BAP, and YKL-40 were analyzed in Cox regression analysis including each biomarker as a time-dependent covariate and updated at each 3 months examination. If no update exists after 7 months, the patient is removed from the risk set and reentered if a subsequent measurement is available. Univariate analysis showed that the ratio of last available serum PINP to the previous measurement (logarithmically transformed and treated as a continuous variable) was significantly associated with early death within 7 months following this measurement [hazard ratio (HR), 2.0; P < 0.0001]. Similar findings were found for serum BAP (HR, 2.1; P < 0.0001) and YKL-40 (HR, 2.1; P < 0.0001). In multivariate Cox analysis, serum PINP and YKL-40 were independent prognostic variables (HR, 1.6; P < 0.0001; and HR, 1.4; P = 0.003, respectively; Table 3 ).


View this table:
[in this window]
[in a new window]

  		Table 3. Univariate and multivariate Cox regression analyses of updated serum PINP, BAP, and YKL-40 values to predict death within the following 7 mo in 106 patients with metastatic PC during hormonal treatment

 

   Discussion
Top
 Abstract
 Patients and Methods
 Results
 Discussion
References
 
The biomarkers of bone formation and serum YKL-40 decreased in patients with metastatic PC after 6 months of treatment with total androgen ablation or parenteral estrogen compared with pretreatment level, probably reflecting the effect of endocrine therapy on osteoblast activity. Serum PINP, BAP, and CTX-I after 6 months of treatment were prognostic parameters of overall survival. Serum PINP at 6 months in combination with baseline WHO grade and Soloway score were independent parameters of short survival. These observations suggest that serum PINP, BAP, and CTX-I at 6 months after start of hormonal treatment of PC patients with bone metastasis may identify a subgroup of patients that is less likely to benefit from this treatment. The study has not evaluated the relationship between these three biomarkers of bone remodeling and quality of life and progression in bone metastasis.

Urine samples were not available in the present study, and the bone resorption marker, serum CTX-I, was only determined 6 months after the start of therapy. In contrast to bone formation markers, serum CTX-I was unchanged at this time point. In patients with localized PC, hormonal therapy increases the bone resorption markers urinary NTX-I (25–27), urinary CTX-I (27), and serum ICTP (28) within 9 weeks to 6 months, whereas no effect was observed on the bone formation markers serum BAP, osteocalcin, and PICP. Thus, short-term hormonal therapy in men with PC leads to a general skeletal increase of bone resorption, which could mask its beneficial effects in reducing bone metastases activity when assessed by a systemic biochemical marker. These opposite effects of hormonal therapy are likely to explain the absence of significant change of serum CTX-I after 6 months in our study of PC patients with skeletal metastasis.

Others have found that the most recent biomarker assessments of urine NTX-I and BAP, taken <6 months before disease progression or death, have greater predictive value of disease progression and time to death than values at diagnosis or start of treatment with bisphosphonates (9, 10). In multivariate analysis, higher levels of serum BAP but not urine NTX-I were associated with shorter overall survival (12). We found that the increases in serum PINP, BAP, and YKL-40 in PC patients with bone metastases during hormonal treatment were predictive parameters of death within the following 7 months. Serum PINP and BAP are closely correlated (both reflect osteoblast activity), but PINP seems to be a more general marker of extracellular matrix building. Others have also reported that serum PINP has prognostic value in metastatic PC and breast cancer (8, 29). The applied PINP ELISA should enable the measurement of {alpha}1-chains of PINP irrespective of the molecular forms because the trimeric structure of PINP is labile at body temperature, and thermal transition from trimeric to monomeric {alpha}1-chains is an ongoing in vivo process (30). The ELISA technology applied in the present study measures the sum of the {alpha}1-chains of PINP irrespective of the molecular form. This is important because the ratio of the trimeric and monomeric PINP varies between individual serum samples (30, 31). It has been proposed that when PC cells invade bone matrix, signaling between these cells causes the release of bone morphogenic proteins from bone matrix to trigger bone formation. New bone formation causes a positive feedback that allows further release of these growth factors, not only from bone matrix but also from the carcinoma cells within the matrix. This cascade compound further stimulates bone formation and proliferation, which leads to osteosclerosis. As more cancer cells invade bone, this cascade leads to increased intra-osseous pressure and periosteal elevation in bone, which causes bone pain and fractures (32).

YKL-40 is produced by cancer cells, including PC (National Center for Biotechnology Information databases; ref. 13) and tumor-associated macrophages (33). High serum YKL-40 at diagnosis is an independent prognostic biomarker of short survival in patients with different types of adeno- and squamous cell cancer, glioblastoma (13), and acute myelogenous leukemia (34). In patients operated for colorectal cancer (35) and stages I-II melanoma (36), significant associations are observed during follow-up between serum YKL-40 (updated continuous covariate) and relapse-free and overall survival, and serum YKL-40 is independent of clinical and histologic parameters (35, 36). Patients operated for high-grade gliomas and no radiographic evidence of disease had lower serum YKL-40 during follow-up than patients with signs of disease (37). High-serum YKL-40 (time-dependent covariate) during follow-up in patients with glioblastoma multiforme and anaplastic astrocytoma is associated with short survival (37).

To conclude, we found that serum PINP, BAP, CTX-I, and YKL-40 could be of value in the monitoring of patients with metastatic PC treated with hormonal therapy. High serum values of these biomarkers combined were related to poor prognosis. This could suggest that a score based on the levels of these biomarkers could be helpful; however, this should be validated in an independent patient cohort.


   Acknowledgments
 
We thank the Scandinavian Prostate Cancer Group-5 (SPCG5) for giving access to the clinical data and the investigators participating in the SPCG5 study group. Inger Aakard (now deceased) of the Department of Rheumatology, Hvidovre Hospital, is greatly appreciated for the measurement of serum YKL-40 and bone alkaline phosphatase. Jette Brandt and Anette Kliem of the Department of Immunology and Microbiology, University of Odense, are thanked for the measurement of serum PINP; and Fabrice Juillet of Molecular Markers, Synarc, for the measurement of serum CTX-I.


   Footnotes
 
Grant support: Dagmar Marshalls Foundation, Danish Medical Research Counsil, Else og Mogens Wedell-Wedellsborg Fond, Michaelsen Fonden, The Aase and Ejnar Danielsens Fund, and Sigvald and Edith Rasmussens Legat. Metra provided the study with YKL-40 and bone alkaline phosphatase ELISA kits. Patients included were part of a Scandinavian Study (Scandinavian Prostate Cancer Group-5) supported by Pharmacia and Upjohn Sverige AB, Lund, Sweden, Schering-Plough AB, Stockholm, Sweden, and Ferring AB, Malmø, Sweden.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/30/06; revised 2/17/07; accepted 3/ 8/07.


   References
Top
 Abstract
 Patients and Methods
 Results
 Discussion
 References
 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30.[Abstract/Free Full Text]
  2. Wilson SS, Crawford ED. Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des 2006;12:799–805.[CrossRef][Medline]
  3. Rozhansky F, Chen MH, Cox MC, et al. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2006;106:63–7.[CrossRef][Medline]
  4. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347–66.[CrossRef][Medline]
  5. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001;27:187–92.[CrossRef][Medline]
  6. Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 2003;97:874–9.[CrossRef][Medline]
  7. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165. Markers of bone remodelling in metastatic bone disease. J Clin Endocrinol Metab 2003;88:5059–75.[Abstract/Free Full Text]
  8. Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111:783–91.[CrossRef][Medline]
  9. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59–69.[Abstract/Free Full Text]
  10. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925–35.[Abstract/Free Full Text]
  11. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503–13.[CrossRef][Medline]
  12. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361–7.[Abstract/Free Full Text]
  13. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Review. Cancer Epidemiol Biomarkers Prev 2006;15:194–202.[Abstract/Free Full Text]
  14. De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926–31.[CrossRef][Medline]
  15. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B–mediated signalling pathways. Biochem J 2002;365:119–26.[CrossRef][Medline]
  16. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoproein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-{alpha}. Biochem J 2004;380:651–9.[CrossRef][Medline]
  17. Recklies AD, Ling H, White C, et al. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005;280:41213–21.[Abstract/Free Full Text]
  18. Bigg HF, Wait R, Rowan AD, et al. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006;281:21082–95.[Abstract/Free Full Text]
  19. Hedlund PO, Henriksson P, and the Scandinavian Prostatic Cancer Group (SPCG)-5 trial study. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology 2000;55:328–33.[CrossRef][Medline]
  20. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195–202.[CrossRef][Medline]
  21. Ørum O, Hansen M, Jensen CH, et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval and hypovitaminosis D–induced hyperparathyroidism. Bone 1996;19:157–63.[Medline]
  22. Gomez B, Jr., Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560–6.[Abstract/Free Full Text]
  23. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001;47:694–702.[Abstract/Free Full Text]
  24. Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem 1998;4:509–16.
  25. Scherr D, Pitts WR, Jr., Vaughn ED, Jr. Diethystilbesterol revised: androgen depricvation, osteoporosis and prostate cancer. J Urol 2002;167:535–8.[CrossRef][Medline]
  26. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotrophin-releasing hormone agonist. J Clin Endocrinol Metab 2001;86:2787–91.[Abstract/Free Full Text]
  27. Taxel P, Fall PM, Albertsen PC, et al. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:4907–13.[Abstract/Free Full Text]
  28. Miyaji Y, Saika T, Yamamoto Y, et al. Effects of gonadotrophin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004;64:128–31.[CrossRef][Medline]
  29. Jensen BV, Johansen JS, Skovsgaard T, et al. Extracellular matrix building marked by the N-terminal propeptide of procollagen type 1 reflect aggressiveness of recurrent breast cancer. Int J Cancer 2002;98:582–9.[CrossRef][Medline]
  30. Brandt J, Krogh TN, Jensen CH, et al. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I (PINP) in relation to assay technology. Clin Chem 1999;45:47–53.[Abstract/Free Full Text]
  31. Jensen CH, Hansen M, Brandt J, et al. Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms. Clin Chim Acta 1998;269:31–41.[CrossRef][Medline]
  32. Reddi AH, Roodman D, Freeman C, et al. Review. Mechanisms of tumour metastasis to the bone: challenges and opportunities. J Bone Miner Res 2003;18:190–4.[CrossRef][Medline]
  33. Junker N, Johansen JS, Andersen CB, et al. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223–31.[CrossRef][Medline]
  34. Bergmann OJ, Johansen JS, Klausen TW, et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res 2005;11:8644–52.[Abstract/Free Full Text]
  35. Cintin C, Johansen JS, Christensen IJ, et al. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002;95:267–74.[CrossRef][Medline]
  36. Schmidt H, Johansen, JS, Sjoegren P, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American joint committee on cancer stage I and II melanoma. J Clin Oncol 2006;24:798–804.[Abstract/Free Full Text]
  37. Hormiga A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006;12:5698–704.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Christensen, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansen, J. S.
Right arrow Articles by Christensen, I. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online